# OnCo record lupeng-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/lupeng-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "lupeng-pharmaceuticals" ;
  schema:name "Lupeng Pharmaceuticals"@en ;
  schema:alternateName "Guangzhou Lupeng Pharmaceutical"@en, "鲁鹏医药"@en ;
  schema:description "Lupeng Pharmaceuticals is a China-based biotechnology company that leads 4 cancer trials in OnCo, testing the Bcl-2 inhibitor lacutoclax (LP-108) and the BTK inhibitor rocbrutinib (LP-168) in chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma."@en ;
  schema:url <https://onco.cc/companies/lupeng-pharmaceuticals/>, <https://www.lupengbio.com/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.lupengbio.com/>, <https://clinicaltrials.gov/search?lead=Guangzhou%20Lupeng%20Pharmaceutical%20Company%20LTD.> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/rocbrutinib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:trials <https://onco.cc/trials/nct07609823/>, <https://onco.cc/trials/nct07609862/>, <https://onco.cc/trials/nct05716087/>, <https://onco.cc/trials/nct07189065/> .